Corneal Persistent Epithelial Defect clinical trials at UCLA
2 research studies open to eligible people
KPI-012 Ophthalmic Solution in Participants With PCED
open to eligible people ages 18 years and up
The primary objective of the study is to investigate the safety and efficacy of KPI-012 compared to vehicle in participants who have a documented clinical diagnosis of PCED.
Los Angeles, California and other locations
NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Chemical and/or Thermal Injuries
open to all eligible people
This study will enroll participants with a non-infected, corneal persistent epithelial defect (PED) resulting from an ocular chemical and/or thermal ocular injury which is non-responsive or refractory to current standard of care for at least 14 days. It will assess the efficacy and safety of Nexagon® (lufepirsen) plus standard of care versus NEXAGON-vehicle (placebo) plus standard of care. The recovery of the corneal epithelium will be the primary outcome measure, defined as a cornea that re-epithelializes by Day 28 of treatment and remains re-epithelialized for at least a further 28 days.
Los Angeles, California and other locations
Our lead scientists for Corneal Persistent Epithelial Defect research studies include Anthony Aldave, MD.
Last updated: